Initiate the STRATUM Phase 3 study for seborrheic dermatitis
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 16 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“anticipating initiation of a single pivotal Phase 3 study (STRATUM) in the second or third quarter of 2021”
What we found
Evidence strength A What the grades mean
A November 2021 8-K says Arcutis announced in July 2021 the initiation of a single pivotal Phase 3 trial for seborrheic dermatitis, within the Q2–Q3 2021 window.
-
A Arcutis Biotherapeutics, Inc. 8-K filed 2021-11-04
“In July, Arcutis announced the initiation of a single pivotal Phase 3 trial for the treatment of seborrheic dermatitis, with topline data anticipated in the second or third quarter of 2022.” ✓ confirmed on the page
-
A Arcutis Biotherapeutics, Inc. 10-Q filed 2021-11-04
“We have also recently initiated pivotal Phase 3 clinical trials of roflumilast cream for the treatment of atopic dermatitis and of roflumilast foam in seborrheic dermatitis and scalp and body psoriasis.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- STRATUM Phase 3 study
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Arcutis Biotherapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ARQT-023949 · Corrections policy